Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 12:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 2,364 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bacterial Infection Clear all
Recruiting Phase 2 Interventional

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

NCT06524635
View directory record Official record
Conditions
Hidradenitis Suppurativa, Atopic Dermatitis
Interventions
Lutikizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Sacramento, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 23, 2026, 12:26 AM EDT
Completed Phase 2 Interventional Results available

A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization

NCT00797108
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
Sulopenem and PF-03709270, Ceftriaxone and amoxicillin/clavulanate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Chula Vista, California • Oceanside, California • Moline, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 23, 2026, 12:26 AM EDT
Terminated Not applicable Interventional Results available

Detection of Borrelia Bacteria in Early Stage Lyme Borreliosis Using the T2Lyme Panel

NCT03581279
View directory record Official record
Conditions
Lyme Disease
Interventions
T2Lyme Panel testing
Device
Lead sponsor
T2 Biosystems
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Wakefield, Rhode Island • La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 23, 2026, 12:26 AM EDT
Completed No phase listed Observational

BIOPIC: Fungal Biomarkers for Diagnosis and Response to Therapy for Pediatric Candidemia

NCT02220790
View directory record Official record
Conditions
Invasive Candidiasis
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
120 Days to 18 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
19
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 23, 2026, 12:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

How Does the Clinical Tool 'What's Going Around' Affect Clinical Practice

NCT01979588
View directory record Official record
Conditions
Influenza Like Illness, Asthma, Group A Streptococcal Infection, Pertussis
Interventions
What's Going Around tool, Control
Other
Lead sponsor
Endeavor Health
Other
Eligibility
Not listed
Enrollment
206,703 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Oct 23, 2026, 12:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa

NCT03275870
View directory record Official record
Conditions
Hidradenitis Suppurativa, Hidradenitis, Acne Inversa, Boils, Follicular Occlusion Triad, Follicular Occlusion Tetrad
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Elena Gonzalez Brant, MD
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 23, 2026, 12:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits

NCT00804713
View directory record Official record
Conditions
Latent Tuberculosis Infection
Interventions
BST, TST, QFT, T-spot
Drug · Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
2,017 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2022
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 23, 2026, 12:26 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety of Solithromycin in Adolescents and Children

NCT02268279
View directory record Official record
Conditions
Bacterial Infection
Interventions
solithromycin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
Up to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
31
States / cities
Little Rock, Arkansas • Orange, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 23, 2026, 12:26 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

NCT03673462
View directory record Official record
Conditions
Healthy Volunteers (Meningococcal Infection)
Interventions
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine), Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®), Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine, Varicella Virus Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,797 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
67
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 23, 2026, 12:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study

NCT00464542
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 23, 2026, 12:26 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Continued Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine

NCT00787826
View directory record Official record
Conditions
Tularemia
Interventions
Live Francisella Tularensis Vaccine
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2021
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Oct 23, 2026, 12:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects

NCT00654108
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Ciprofloxacin, Peru-15-pCTB, Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 23, 2026, 12:26 AM EDT
Completed Not applicable Interventional

A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common

NCT00002325
View directory record Official record
Conditions
Mycoses, HIV Infections, Coccidioidomycosis
Interventions
Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Phoenix, Arizona • Tucson, Arizona • Rancho Mirage, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 12:26 AM EDT
Completed Phase 1Phase 2 Interventional

Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis

NCT01020396
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older · Female only
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
37
States / cities
Huntsville, Alabama • Fountain Valley, California • Washington D.C., District of Columbia + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 23, 2026, 12:26 AM EDT
Completed Phase 3 Interventional

Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units

NCT00099775
View directory record Official record
Conditions
Candidiasis
Interventions
Caspofungin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 12:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis

NCT00796809
View directory record Official record
Conditions
Coccidioidomycosis, Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
Not listed
Enrollment
598 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 23, 2026, 12:26 AM EDT
Completed No phase listed Observational

Rapid Characterization of Paucibacillary TB Along Tex/Mex Border

NCT00421798
View directory record Official record
Conditions
Mycobacterium Tuberculosis
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 85 Years
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Brownsville, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2009 · Synced Oct 23, 2026, 12:26 AM EDT
Completed Phase 3 Interventional

A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections

NCT00002277
View directory record Official record
Conditions
Mycoses, HIV Infections
Interventions
Fluconazole, Amphotericin B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 12:26 AM EDT
Active, not recruiting Phase 2 Interventional

Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia

NCT05776004
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
CAL02, Placebo
Drug
Lead sponsor
Eagle Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Fresno, California • Gainesville, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 23, 2026, 12:26 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

NCT00061633
View directory record Official record
Conditions
Infections, Gram-Positive Bacterial, Abscess, Burns, Cellulitis, Ulcer, Wound Infections
Interventions
Telavancin, Vancomycin or antistaphylococcal penicillin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 23, 2026, 12:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine

NCT01447407
View directory record Official record
Conditions
Staphylococcal Infections, Yeast Infections, Candidiasis
Interventions
NDV-3 vaccine with alum IM, NDV-3 vaccine without alum IM, Placebo with alum IM, NDV-3 vaccine without alum ID
Biological
Lead sponsor
NovaDigm Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 23, 2026, 12:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

NCT01823536
View directory record Official record
Conditions
Meningococcal Disease
Interventions
Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
7 Years to 15 Years
Enrollment
465 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
15
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Downey, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Oct 23, 2026, 12:26 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria

NCT03580044
View directory record Official record
Conditions
Serious Bacterial Infection
Interventions
ATM-AVI, BAT
Combination Product · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 23, 2026, 12:26 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

NCT00269399
View directory record Official record
Conditions
Clostridium Infections, Diarrhea
Interventions
Rifaximin (Xifaxan), Vancomycin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
63
States / cities
Scottsdale, Arizona • Redlands, California • Longmont, Colorado + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 23, 2026, 12:26 AM EDT